Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
Abstract The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real‐world utilizat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224393959407616 |
|---|---|
| author | Daisuke Goto Rahul Khairnar Jean A. Yared Candice Yong Dorothy Romanus Eberechukwu Onukwugha Julia F. Slejko |
| author_facet | Daisuke Goto Rahul Khairnar Jean A. Yared Candice Yong Dorothy Romanus Eberechukwu Onukwugha Julia F. Slejko |
| author_sort | Daisuke Goto |
| collection | DOAJ |
| description | Abstract The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real‐world utilization of these new agents has not been studied well. This study evaluated year‐to‐year changes in treatment choices in a cohort of patients aged 66 or older in the Surveillance, Epidemiology, and End Results (SEER) registry linked with Medicare claims (SEER‐Medicare) data who were diagnosed with MM between 2007 and 2011. We identified 2477 symptomatic newly diagnosed patients who were followed for 6 months or more postdiagnosis and treated with systemic therapies but not with stem cell transplantation. Symptomatic patients were identified by evidence of hypercalcemia, renal failure, anemia, or bone lesions (CRAB criteria). The minimum follow‐up was imposed to ensure sufficient data to characterize treatment. Our analysis found that the proportion of treated patients increased from 75% in the 2007 cohort to 79% in the 2011 cohort. The share of PI‐based regimens including PI plus alkylating agents, PI plus IMiD, and PI‐only increased from 9% to 21%, 3% to 11%, and 16% to 22%, respectively, between 2007 and 2011. These findings translate to the share of PI‐based regimens having increased from 28% to 55% and that of IMiDs‐based regimens (excluding PI plus IMiD) having decreased from 43% to 27%. In conclusion, while the usage of PIs among elderly MM patients increased significantly replacing IMiD‐based regimens (with or without alkylating agents but not with PI) between 2007 and 2011, this significant shift did not increase the proportion of treated patients. |
| format | Article |
| id | doaj-art-c2dcfdfc6c454f1680acb8474f5a49ea |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-c2dcfdfc6c454f1680acb8474f5a49ea2025-08-25T10:14:05ZengWileyCancer Medicine2045-76342020-01-019262663910.1002/cam4.2698Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare dataDaisuke Goto0Rahul Khairnar1Jean A. Yared2Candice Yong3Dorothy Romanus4Eberechukwu Onukwugha5Julia F. Slejko6Merck Research Laboratories North Wales PA USADepartment of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USADepartment of Medicine University of Maryland School of Medicine Baltimore MD USAAstraZeneca Pharmaceuticals LP Gaithersburg MD USAMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USADepartment of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USADepartment of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USAAbstract The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real‐world utilization of these new agents has not been studied well. This study evaluated year‐to‐year changes in treatment choices in a cohort of patients aged 66 or older in the Surveillance, Epidemiology, and End Results (SEER) registry linked with Medicare claims (SEER‐Medicare) data who were diagnosed with MM between 2007 and 2011. We identified 2477 symptomatic newly diagnosed patients who were followed for 6 months or more postdiagnosis and treated with systemic therapies but not with stem cell transplantation. Symptomatic patients were identified by evidence of hypercalcemia, renal failure, anemia, or bone lesions (CRAB criteria). The minimum follow‐up was imposed to ensure sufficient data to characterize treatment. Our analysis found that the proportion of treated patients increased from 75% in the 2007 cohort to 79% in the 2011 cohort. The share of PI‐based regimens including PI plus alkylating agents, PI plus IMiD, and PI‐only increased from 9% to 21%, 3% to 11%, and 16% to 22%, respectively, between 2007 and 2011. These findings translate to the share of PI‐based regimens having increased from 28% to 55% and that of IMiDs‐based regimens (excluding PI plus IMiD) having decreased from 43% to 27%. In conclusion, while the usage of PIs among elderly MM patients increased significantly replacing IMiD‐based regimens (with or without alkylating agents but not with PI) between 2007 and 2011, this significant shift did not increase the proportion of treated patients.https://doi.org/10.1002/cam4.2698elderly patientsimmunomodulatory drugs (IMiDs)multiple myelomaproteasome inhibitorsSEER‐Medicaresystemic treatment |
| spellingShingle | Daisuke Goto Rahul Khairnar Jean A. Yared Candice Yong Dorothy Romanus Eberechukwu Onukwugha Julia F. Slejko Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data Cancer Medicine elderly patients immunomodulatory drugs (IMiDs) multiple myeloma proteasome inhibitors SEER‐Medicare systemic treatment |
| title | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data |
| title_full | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data |
| title_fullStr | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data |
| title_full_unstemmed | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data |
| title_short | Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data |
| title_sort | utilization of novel systemic therapies for multiple myeloma a retrospective study of front line regimens using the seer medicare data |
| topic | elderly patients immunomodulatory drugs (IMiDs) multiple myeloma proteasome inhibitors SEER‐Medicare systemic treatment |
| url | https://doi.org/10.1002/cam4.2698 |
| work_keys_str_mv | AT daisukegoto utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata AT rahulkhairnar utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata AT jeanayared utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata AT candiceyong utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata AT dorothyromanus utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata AT eberechukwuonukwugha utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata AT juliafslejko utilizationofnovelsystemictherapiesformultiplemyelomaaretrospectivestudyoffrontlineregimensusingtheseermedicaredata |